Oncogenic alterations in FGFR1-4, including short variants (SVs), gene rearrangements (REs; i.e. movement of DNA gene sequences across the genome, which may lead to gene fusions), and copy number alterations (CNAs), are found in ∼7% of all human cancers, most commonly in urothelial, breast, endometrial, squamous lung, and ovarian cancer, and in cholangiocarcinoma.1 Here, FGFR1 is linked to cholangiocarcinoma.